1. Home
  2. RCKT vs CMPR Comparison

RCKT vs CMPR Comparison

Compare RCKT & CMPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCKT
  • CMPR
  • Stock Information
  • Founded
  • RCKT 1999
  • CMPR 1994
  • Country
  • RCKT United States
  • CMPR Ireland
  • Employees
  • RCKT N/A
  • CMPR N/A
  • Industry
  • RCKT Biotechnology: Pharmaceutical Preparations
  • CMPR Publishing
  • Sector
  • RCKT Health Care
  • CMPR Consumer Discretionary
  • Exchange
  • RCKT Nasdaq
  • CMPR Nasdaq
  • Market Cap
  • RCKT 326.4M
  • CMPR 1.1B
  • IPO Year
  • RCKT N/A
  • CMPR N/A
  • Fundamental
  • Price
  • RCKT $2.90
  • CMPR $49.68
  • Analyst Decision
  • RCKT Buy
  • CMPR Strong Buy
  • Analyst Count
  • RCKT 13
  • CMPR 2
  • Target Price
  • RCKT $18.50
  • CMPR $62.50
  • AVG Volume (30 Days)
  • RCKT 4.3M
  • CMPR 321.9K
  • Earning Date
  • RCKT 08-04-2025
  • CMPR 07-30-2025
  • Dividend Yield
  • RCKT N/A
  • CMPR N/A
  • EPS Growth
  • RCKT N/A
  • CMPR 83.61
  • EPS
  • RCKT N/A
  • CMPR 5.97
  • Revenue
  • RCKT N/A
  • CMPR $3,366,207,000.00
  • Revenue This Year
  • RCKT N/A
  • CMPR $4.65
  • Revenue Next Year
  • RCKT N/A
  • CMPR $3.16
  • P/E Ratio
  • RCKT N/A
  • CMPR $8.34
  • Revenue Growth
  • RCKT N/A
  • CMPR 3.64
  • 52 Week Low
  • RCKT $2.19
  • CMPR $35.21
  • 52 Week High
  • RCKT $26.98
  • CMPR $104.92
  • Technical
  • Relative Strength Index (RSI)
  • RCKT 41.69
  • CMPR 66.92
  • Support Level
  • RCKT $2.40
  • CMPR $45.78
  • Resistance Level
  • RCKT $2.70
  • CMPR $50.82
  • Average True Range (ATR)
  • RCKT 0.21
  • CMPR 1.96
  • MACD
  • RCKT 0.15
  • CMPR 0.52
  • Stochastic Oscillator
  • RCKT 73.53
  • CMPR 87.00

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

About CMPR Cimpress plc (Ireland)

Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.

Share on Social Networks: